Surgical Science Sweden AB

Surgical Science Sweden AB's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Surgical Science Sweden AB has 51.03M shares outstanding.

As of June 30, 2026, Surgical Science Sweden AB maintains a current ratio of 4.20, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Surgical Science Sweden AB posted a return on equity (ROE) of 2.10, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.05 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.92, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.10, useful for judging operating efficiency across full business cycles. The company generates approximately 304,413.95 in revenue per employee across its workforce of 303.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.55 indicates how many times Surgical Science Sweden AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Surgical Science Sweden AB recorded 2.97M in income tax expense. That works out to an effective tax rate of 26.11, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.38M, leaving 8.41M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Surgical Science Sweden AB generated 92.31M in revenue and converted that into 8.41M in net income, yielding earnings per share of 0.16. EBITDA reached 11.10M, while operating income came in at 11.10M.

As of June 30, 2026, Surgical Science Sweden AB holds 59.44M in cash and equivalents against 257,937.20 in total debt, resulting in a net debt position of -59.18M. Total book value stands at 410.86M, with working capital of 86.69M providing operational flexibility.

Surgical Science Sweden AB produced 13.46M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -5.94M in capital expenditures, free cash flow totaled 7.52M - equivalent to 0.15 per share.

Over the twelve months ended June 30, 2026, Surgical Science Sweden AB posted a gross margin of 66.50, reflecting its pricing power and cost economics. The operating margin of 12.02 and net profit margin of 9.11 provide insight into operational efficiency.

Surgical Science Sweden AB's most recent stock split took place on May 25, 2020 with a 1:5 split ratio.